

Apostolos Apostolidis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9428468/publications.pdf>

Version: 2024-02-01

50
papers

1,344
citations

535685

17
h-index

388640

36
g-index

63
all docs

63
docs citations

63
times ranked

1251
citing authors

#	ARTICLE	IF	CITATIONS
1	Do we have enough evidence to propose a urinary biomarker of bladder ischemia? A systematic review and meta-analysis. LUTS: Lower Urinary Tract Symptoms, 2022, , .	0.6	1
2	The effect of pharmacotherapy on prostate volume, prostate perfusion and prostate-specific antigens (prostate morphometric parameters) in patients with lower urinary tract symptoms and benign prostatic obstruction. A systematic review and meta-analysis. Central European Journal of Urology, 2021, 74, 388-421.	0.2	2
3	The Effect of Low-Intensity Extracorporeal Shockwave Treatment on the Urinary Bladder in an Experimental Diabetic Rat Model. International Neurourology Journal, 2021, 25, 34-41.	0.5	4
4	Detrusor Overactivity May Be a Prognostic Factor for Better Response to Combination Therapy Over Monotherapy in Male Patients With Benign Prostatic Enlargement and Storage Lower Urinary Tract Symptoms. International Neurourology Journal, 2021, 25, 69-76.	0.5	2
5	Low-intensity shockwave therapy for the management of chronic prostatitis/chronic pelvic pain syndrome: a systematic review and meta-analysis. BJU International, 2021, 128, 144-152.	1.3	18
6	The use of urinary biomarkers in the diagnosis of overactive bladder in female patients. A systematic review and meta-analysis. International Urogynecology Journal, 2021, 32, 3143-3155.	0.7	10
7	Defining Voiding Dysfunction in Women: Bladder Outflow Obstruction Versus Detrusor Underactivity. International Neurourology Journal, 2021, 25, 244-251.	0.5	14
8	DNA Hypermethylation of a Panel Of Genes as an Urinary Biomarker For Bladder Cancer Diagnosis. Urology Journal, 2021, , .	0.3	2
9	Botulinum toxin A for refractory OAB and idiopathic urinary retention: Can phenotyping improve outcome for patients: ICIERS 2019?. Neurourology and Urodynamics, 2020, 39, S104-S112.	0.8	3
10	Can we improve our diagnosis of impaired detrusor contractility in women? An ICIERS 2019 proposal. Neurourology and Urodynamics, 2020, 39, S43-S49.	0.8	3
11	Sacral nerve stimulation for refractory OAB and idiopathic urinary retention: Can phenotyping improve the outcome for patients: ICIERS 2019?. Neurourology and Urodynamics, 2020, 39, S96-S103.	0.8	0
12	Should we routinely assess psychological morbidities in idiopathic lower urinary tract dysfunction: ICIERS 2019?. Neurourology and Urodynamics, 2020, 39, S70-S79.	0.8	2
13	Healthcare Access, Quality, and Satisfaction Among Albanian Immigrants Using the Emergency Department in Northern Greece. Journal of Immigrant and Minority Health, 2020, 22, 512-525.	0.8	5
14	Intravesical Botox for Overactive Bladder: How to Minimize Complications and Manage Failures. Current Drug Targets, 2020, 21, 1527-1536.	1.0	3
15	Is there enough evidence to support sacral neuromodulation as a viable treatment option in children and adolescents with neurogenic lower urinary tract dysfunction?. World Journal of Urology, 2019, 37, 2811-2812.	1.2	2
16	Are psychological comorbidities important in the aetiology of lower urinary tract dysfunction? ICIERS 2018?. Neurourology and Urodynamics, 2019, 38, S8-S17.	0.8	12
17	Can we improve our management of dysfunctional voiding in children and adults: International Consultation on Incontinence Research Society; ICIERS2018?. Neurourology and Urodynamics, 2019, 38, S82-S89.	0.8	5
18	Stem cells and lower urinary tract dysfunction: Has its potential finally reached clinical maturity? ICIERS2018. Neurourology and Urodynamics, 2019, 38, S134-S141.	0.8	4

#	ARTICLE	IF	CITATIONS
19	Is there a brain OAB and how can we recognize it? International Consultation on Incontinence Research Society (ICIRS) 2017. <i>Neurourology and Urodynamics</i> , 2018, 37, S38-S45.	0.8	13
20	The efficacy of botulinum toxin A and sacral neuromodulation in the management of interstitial cystitis (IC)/bladder pain syndrome (BPS), what do we know? ICIRS 2017 think tank, Bristol. <i>Neurourology and Urodynamics</i> , 2018, 37, S99-S107.	0.8	19
21	Do we understand voiding dysfunction in women? Current understanding and future perspectives: ICIRS 2017. <i>Neurourology and Urodynamics</i> , 2018, 37, S75-S85.	0.8	20
22	Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: Results from a randomized pilot study. <i>International Journal of Urology</i> , 2018, 25, 737-745.	0.5	8
23	Subtle errors of bladder wall thickness measurement have a significant impact on the calculation of ultrasound-estimated bladder weight. A pilot study. <i>Medical Ultrasonography</i> , 2018, 20, 292.	0.4	0
24	How does lower urinary tract dysfunction (LUTD) affect sexual function in men and women? ICIRS 2015 Part 2. <i>Neurourology and Urodynamics</i> , 2017, 36, 869-875.	0.8	9
25	The urinary microbiome and its contribution to lower urinary tract symptoms; ICIRS 2015. <i>Neurourology and Urodynamics</i> , 2017, 36, 850-853.	0.8	39
26	How does lower urinary tract dysfunction affect sexual function in men and women? ICIRS 2015 Part 1. <i>Neurourology and Urodynamics</i> , 2017, 36, 949-952.	0.8	9
27	Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICIRS 2015). <i>Neurourology and Urodynamics</i> , 2017, 36, 882-893.	0.8	44
28	Combination treatments for overactive bladder refractory to first-line pharmacotherapy: do they meet expectations?. <i>BJU International</i> , 2017, 120, 459-460.	1.3	2
29	Do we understand how botulinum toxin works and have we optimized the way it is administered to the bladder? ICIRS 2014. <i>Neurourology and Urodynamics</i> , 2016, 35, 293-298.	0.8	20
30	Retrograde transport of radiolabelled botulinum neurotoxin type A to the CNS after intradetrusor injection in rats. <i>BJU International</i> , 2016, 117, 697-704.	1.3	32
31	Recommendations for future development of contractility and obstruction nomograms for women. ICIRS 2014. <i>Neurourology and Urodynamics</i> , 2016, 35, 307-311.	0.8	14
32	Re: Intrathecal Administration of Botulinum Toxin Type A Improves Urinary Bladder Function and Reduces Pain in Rats with Cystitis. <i>European Urology</i> , 2015, 67, 816.	0.9	1
33	Antimuscarinics in the Treatment of OAB: Is there a First-Line and a Second-Line Choice?. <i>Current Drug Targets</i> , 2015, 16, 1187-1197.	1.0	16
34	An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity. <i>World Journal of Urology</i> , 2013, 31, 1469-1474.	1.2	38
35	Male Lower Urinary Tract Symptoms: A Riddle Waiting to Be Solved. <i>European Urology</i> , 2013, 64, 408-410.	0.9	4
36	Treatment of Overactive Bladder with Botulinum Toxin: Are There More Challenges to Deal With?. <i>European Urology</i> , 2012, 62, 515-517.	0.9	2

#	ARTICLE	IF	CITATIONS
37	What determines whether a patient with LUTS seeks treatment?: ICIâ€™RS 2011. Neurourology and Urodynamics, 2012, 31, 365-369.	0.8	24
38	Taming the Cannabinoids: New Potential in the Pharmacologic Control of Lower Urinary Tract Dysfunction. European Urology, 2012, 61, 107-109.	0.9	13
39	Pharmacotherapy for overactive bladder: minimally invasive treatment â€™ botulinum toxins. Expert Opinion on Pharmacotherapy, 2011, 12, 1029-1039.	0.9	5
40	Editorial Comment. Urology, 2011, 78, e1.	0.5	19
41	Neuromodulation for intractable OAB. Neurourology and Urodynamics, 2011, 30, 766-770.	0.8	22
42	Current Status of Botulinum Toxin for Neurogenic Bladder Dysfunction. Current Bladder Dysfunction Reports, 2010, 5, 87-97.	0.2	0
43	Recommendations on the Use of Botulinum Toxin in the Treatment of Lower Urinary Tract Disorders and Pelvic Floor Dysfunctions: A European Consensus Report. European Urology, 2009, 55, 100-120.	0.9	269
44	Editorial Comment on: Tension-Free Vaginal Tape in the Management of Recurrent Urodynamic Stress Incontinence after Previous Failed Midurethral Tape. European Urology, 2009, 55, 1457-1458.	0.9	0
45	Gender and Age Differences in the Perception of Bother and Health Care Seeking for Lower Urinary Tract Symptoms: Results from the Hospitalised and Outpatientsâ€™™ Profile and Expectations Study. European Urology, 2009, 56, 937-947.	0.9	48
46	Short-term efficacy of group pelvic floor training under intensive supervision versus unsupervised home training for female stress urinary incontinence: A randomized pilot study. Neurourology and Urodynamics, 2007, 26, 486-491.	0.8	45
47	Proposed Mechanism for the Efficacy of Injected Botulinum Toxin in the Treatment of Human Detrusor Overactivity. European Urology, 2006, 49, 644-650.	0.9	294
48	Quality of Life Changes in Patients with Neurogenic versus Idiopathic Detrusor Overactivity after Intradetrusor Injections of Botulinum Neurotoxin Type A and Correlations with Lower Urinary Tract Symptoms and Urodynamic Changes. European Urology, 2006, 49, 528-535.	0.9	115
49	CORPOROPLASTY USING TUNICA ALBUGINEA FREE GRAFTS FOR PENILE CURVATURE: SURGICAL TECHNIQUE AND LONG-TERM RESULTS. Journal of Urology, 2002, 167, 1367-1370.	0.2	42
50	Diagnostic Steps In The Evaluation Of Patients With Erectile Dysfunction. Journal of Urology, 2002, 168, 615-620.	0.2	66